Gene · 136
ADORA2B: adenosine A2b receptor
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADORA2B: adenosine A2b receptor. Genes, record 136. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/136
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P29275 | Adenosine receptor A2b | 332 | 4 | Ensembl, GeneID, HGNC |
Source UniProt
Patents84
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 36624 | P29275 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 4283 | P29275 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 225 | P29275 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 329 | P29275 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 329 | P29275 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 4283 | P29275 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 2683 | P29275 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24229 | P29275 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 225 | P29275 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 24229 | P29275 | Espacenet |
1 to 10 of 84
See all 84 patentsDrugs15
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ADENOSINE | CHEMBL477 | Adenosine receptor agonist | AGONIST | ChEMBL |
| AMINOPHYLLINE | CHEMBL1370561 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAFFEINE | CHEMBL113 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| CAFFEINE CITRATE | CHEMBL1200569 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| DEFIBROTIDE | CHEMBL2108396 | Adenosine A2 receptor agonist | AGONIST | ChEMBL |
| ETRUMADENANT | CHEMBL4740383 | Adenosine A2b receptor antagonist | ANTAGONIST | ChEMBL |
| GS 6201 | CHEMBL260933 | Adenosine A2b receptor antagonist | ANTAGONIST | ChEMBL |
| LAS101057 | CHEMBL1672627 | Adenosine A2b receptor antagonist | ANTAGONIST | ChEMBL |
| OXTRIPHYLLINE | CHEMBL1200434 | Adenosine receptor antagonist | ANTAGONIST | ChEMBL |
| PENTOXIFYLLINE | CHEMBL628 | Adenosine A2 receptor antagonist | ANTAGONIST | ChEMBL |
1 to 10 of 15
See all 15 drugsTrials295
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07469852 | CAFFEINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07466732 | CAFFEINE | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07456670 | CAFFEINE | PHASE2 | ClinicalTrials.gov | |
| NCT07349472 | PENTOXIFYLLINE | PHASE2 | ClinicalTrials.gov | |
| NCT07348510 | AMINOPHYLLINE | ClinicalTrials.gov | ||
| NCT07315139 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT07262060 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07252518 | PENTOXIFYLLINE | ClinicalTrials.gov | ||
| NCT07216365 | CAFFEINE CITRATE | PHASE2 | ClinicalTrials.gov | |
| NCT07088328 | PENTOXIFYLLINE | ClinicalTrials.gov |
1 to 10 of 295
See all 295 trialsNIH grants855
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADORA2B papers | Newest fiscal year |
|---|---|---|---|
| R01DK095491 | Indole dysbiosis and mucosal inflammation | 14 | 2025 |
| I01BX002182 | Metabolic Regulation of Mucosal Inflammation | 8 | 2025 |
| R01DK104713 | Metabolic Regulation of Inflammation by Microbial SCFA | 8 | 2025 |
| ZIADK031117 | Development of Drugs Acting at Adenosine Receptors | 5 | 2025 |
| P30DK056338 | Texas Medical Center Digestive Diseases Center | 4 | 2025 |
| R01HL155950 | Targeting Myeloid Dependent MicroRNAs in Acute Respiratory Distress Syndrome | 4 | 2025 |
| R01HL146442 | The role of ferroptosis in red cell aging in vivo and in vitro | 3 | 2025 |
| R01HL161004 | The paradoxical response to iron in pulmonary hypertension of sickle cell disease | 3 | 2025 |
| T32GM135118 | Research Training of Anesthesiology Physician-Scientists | 3 | 2025 |
| P01CA013106 | Targeting Transcription and Splicing in Cancer | 2 | 2025 |
1 to 10 of 855Source NIH's project files
See all 855 nih grantsPapers1,219
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Stromal spatial signatures of the classical adenosine pathway dictate prognosis in hepatocellular carcinoma. | Immunol Lett | 2026 | 42815694 | PubTator, text mining | PubMed |
| TRPV4-driven ATP release activates CFTR through ADORA2B and P2RY2 receptors in the airway epithelium. | iScience | 2026 | 42707181 | PubTator, text mining | PubMed |
| Increased ADORA1 expression in pancreatic islets coincides with insulin secretory defects in human type 2 diabetes. | J Biol Chem | 2026 | 42660457 | PubTator, text mining | PubMed |
| CD73 is associated with glycolysis-related metabolic features in head and neck squamous cell carcinoma. | Eur J Oral Sci | 2026 | 42605821 | PubTator, text mining | PubMed |
| Adenosine-A Regulator of Human Testicular Peritubular Cells. | Andrology | 2026 | 42444403 | PubTator, text mining | PubMed |
| Adenosine A2B Receptor Activation: A Novel Therapeutic Strategy for Accelerating Liver Recovery After Acetaminophen Overdose. | bioRxiv | 2026 | 42427683 | PubTator, text mining | PubMed |
| Clemastine alleviates cognitive dysfunction after SAH by targeting neuronal CNTN1 to regulate the ADA-adenosine pathway. | Acta Pharmacol Sin | 2026 | 42337055 | PubTator, text mining | PubMed |
| Expression of adenosine A1, A2A, A2B, and A3 receptors in ovarian cancer: their clinical potential in diagnosis and prognosis. | Mol Biol Rep | 2026 | 42234312 | PubTator, text mining | PubMed |
Integration of network toxicology, WGCNA, and explainable machine learning to decipher the toxic molecular basis underlying DEGDB plasticizer-induced clear cell renal cell carcinoma (ccRCC) progression. | Comput Biol Chem | 2026 | 42224996 | PubTator, text mining | PubMed |
| Targeting purinergic signaling and MTAP-associated metabolism in cancer: A functional immunometabolic convergence framework. | Biochem Pharmacol | 2026 | 42082122 | PubTator, text mining | PubMed |
1 to 10 of 1,219
See all 1,219 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/136
GET https://conductscience.org/api/genes/v1/136/patents?page=2